- Summer Street is out with some commentary on Intercept Pharmaceuticals (ICPT -5.7%).
- "There is extensive Phase 2 data in primary biliary cirrhosis," analyst Bart Classen says, noting that based on this data, Summer Street "think[s] the current Phase 3 trial has a favorable chance of meeting its primary endpoint."
- That said, Classen calls OCA's chances in NASH "highly speculative," and adds that "there is also little evidence that OCA will be effective in portal hypertension."
Summer Street cautious on some indications for Intercept's obeticholic acid
Dec 16 2013, 13:08 ET